Added to YB: 2025-02-26
Pitch date: 2025-02-24
STOK [bullish]
Stoke Therapeutics, Inc.
+250.71%
current return
Author Info
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Market Cap
$1.9B
Pitch Price
$8.46
Price Target
20.20 (-32%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-10.68
EV/Sales
N/A
Sector
Biotechnology
Category
value
Show full summary:
Weekend thoughts: Opportunities in small biopharma
STOK: Trading at $8.33, just $1/share above $385M net cash. Biogen deal values ex-US rights at ~$500M NPV. US rights est. worth $350M. Total asset value ~$20.20/share. Phase 3 trial risk, but Biogen partnership validates potential. Sector-wide biotech undervaluation opportunity.
Read full article (7 min)